Key Highlights
- Published market data put the stock 51.45% lower, at USD 6.85, on Tuesday, November 17, 2026. Dividing by 0.4855 implies a prior close near USD 14.11, a calculated figure rather than a verified quote.
- Cash stood at USD 57.9 million for the period ended September 30, 2026, against USD 27.1 million at year-end 2025, while the third-quarter net loss grew to USD 50.0 million from USD 7.4 million.
- The 10-Q says the nine-month net loss of USD 208.3 million contains USD 59.4 million of stock-based compensation and a non-cash loss of roughly USD 90.0 million tied to liability-classified warrants.
- The 10-Q cover lists 8,359,523 shares outstanding on November 13, 2026, after a 1-for-30 reverse split effective April 23, 2026 that reduced the count from roughly 97.7 million to roughly 3.3 million.
No Dated Company Announcement Accounts for the 51.45% Slide
In published market data on Tuesday, November 17, 2026, Cue Biopharma (NASDAQ:CUE) stock showed a 51.45% decline to USD 6.85. Searches turned up no press release, trial update or financing notice for November 14 to November 17, so the cause remains unconfirmed. Dividing USD 6.85 by 0.4855 yields a prior close of roughly USD 14.11, which is calculated and should not be taken as a verified quote. With so few shares in circulation, a move this large can come from a handful of trades, wide spreads and quotes that later reverse.
Reading the Quarterly Report for September 30
The 10-Q for the period ended September 30, 2026 lists cash and equivalents of USD 57.9 million, compared with USD 27.1 million at the end of 2025. Collaboration Revenue slipped to USD 0.1 million for the quarter from USD 2.1 million a year earlier, yet nine-month revenue climbed to USD 13.7 million from USD 5.5 million. The quarterly net loss swelled to USD 50.0 million from USD 7.4 million, and the nine-month loss came to USD 208.3 million. The filing says USD 59.4 million of stock-based compensation and a non-cash loss near USD 90.0 million from issuing liability-classified warrants sit inside that nine-month total, so actual cash burn is smaller than the headline loss.
A Reverse Split, a Growing Share Count and Early-Stage Trial Risk
Shareholders approved a 1-for-30 reverse split at the April 13, 2026 annual meeting, and it became effective on April 23, 2026, partly to restore compliance with the Nasdaq minimum bid price rule. The count went from about 97.7 million to about 3.3 million, with the 10-Q cover listing 8,359,523 as of November 13, 2026, compared with 7,753,995 on September 30. Cue Biopharma (NASDAQ:CUE) also priced a USD 10 million offering on December 19, 2025, for 35,714,286 shares or pre-funded warrants, plus warrants on 17,857,143 shares. CUE-401, an autoimmune candidate, entered Phase 1 dosing in October 2026, and early-stage results carry a high chance of failure. Management expects cash to fund operations for at least twelve months, though long-term viability hinges on raising more capital.
Where Things Stand
Nothing from the company explains the 51.45% fall, so for now it is best treated as unexplained. Cue Biopharma (NASDAQ:CUE) holds more cash than it did at the end of last year, has its lead autoimmune candidate in a Phase 1 trial and depends on future Capital for its funding outlook. Offsetting that, the quarterly loss widened sharply, partly on non-cash Warrant and share-based pay charges, while the reverse split has been followed by a larger share count. Watch for any company filing or release addressing the move, the date of the 10-Q filing, early CUE-401 data and any fresh financing. On a small share count, a quoted move can unwind once Volume settles.
_11_17_2026_18_59_44_560836.jpg)





Please wait processing your request...